Health · 1 sources covering this

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/aa56123a04b0a9d2460df07ee9db4ac5f2adf973"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study"></iframe>

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

How 1 sources are covering this

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

More from Health

STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more

In Nebraska, Americans begin to lose Medicaid under Trump's work rules

Federal government could improve infectious disease monitoring, says federal government

One Big Beautiful Bill cut healthcare funds. Now, Republicans have to sell the costs

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study

More from Health

STAT+: Pharmalittle: We&#8217;re reading about a Novo setback, support for Replimune&#8217;s melanoma drug, and more

In Nebraska, Americans begin to lose Medicaid under Trump's work rules

Federal government could improve infectious disease monitoring, says federal government

One Big Beautiful Bill cut healthcare funds. Now, Republicans have to sell the costs

Reader

Trust & legal

Across the network

STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more